Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

By Manenti L.   Paganoni P.   Floriani I.   Landoni F.   Torri V.   Buda A.   Taraboletti G.   Labianca R.   Belotti D.   Giavazzi R.  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1948-1956

Elsevier

Access to resources Recommend Favorite

Regulation of membrane type-matrix metalloproteinases

By Hernandez-Barrantes S.   Bernardo M.   Toth M.   Fridman R.  

Seminars in Cancer Biology, Vol. 12, Iss. 2, 2002-04 ,pp. : 131-138

Academic Press

Access to resources Recommend Favorite

Aflibercept in epithelial ovarian carcinoma

By Moroney John W   Sood Anil K   Coleman Robert L  

Future Oncology, Vol. 5, Iss. 5, 2009-06 ,pp. : 591-600

Future Medicine

Access to resources Recommend Favorite

Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma

By Davidson Ben   Givant-Horwitz Vered   Lazarovici Philip   Risberg Björn   Nesland Jahn   Trope Claes   Schaefer Erik   Reich Reuven  

Clinical and Experimental Metastasis, Vol. 20, Iss. 7, 2003-11 ,pp. : 621-631

Springer Publishing Company

Access to resources Recommend Favorite

Downregulation of matrix metalloproteinase 9 by small interfering RNA inhibits the tumor growth of ovarian epithelial carcinoma in vitro and in vivo

By          

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 753-759

Spandidos Publications

Access to resources Recommend Favorite